uniQure/CSL’s EtranaDez Could Take Lead Position In Hemophilia B Gene Therapy Market
The therapy could also face competition from players like Freeline, but new Phase III data position uniQure and CSL Behring well for planned FDA and EMA filings.
You may also be interested in...
After highlighting oncology drugs pegged to make a splash next year with the help of Biomedtracker, Scrip takes a look at seven potential blockbusters across a range of therapeutic areas including neurology, dermatology and blood disorders slated for approval next year.
The latest NDA and BLA submission news and highlights from the Pink Sheet’s US FDA Performance Tracker
The sponsors of two monoclonal antibody products, tislelizumab and tremelimumab, are each seeking marketing approval for more than one indication.